Aim: Defects in β cell differentiation are associated with type 2 diabetes in humans. Understanding the basis for β cell differentiation defects may reveal new strategies for diabetes therapy.

Results: We found that Growth factor receptor binding protein 10 (Grb10) is highly expressed in mouse and human pancreas and islets and that β cell-specific knockout of Grb10 in mice increased β-cell mass and insulin content, enhanced insulin secretion from β-cells, and up-regulated mTOR and insulin signaling in islets. Pancreatic β cell-specific disruption of Grb10 expression also improved glucose tolerance in mice fed with a high fat diet and protected adult mice from STZ-induced β cell death. Pancreas-specific knockout Grb10 promoted endocrine progenitors differentiate into β cells during embryonic development. In addition, knockout Grb10 in islets alleviated STZ or high fat diet-induced β cell dedifferentiation.

Conclusion: We have identified Grb10 as a key regulator of β cells differentiation/dedifferentiation and demonstrated that reducing the expression level of Grb10 has a protective effect on β-cell function. Our findings suggest a potential effective therapeutic treatment of both type 1 and type 2 diabetes.

Disclosure

J. Zhang: None. Z. Cai: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.